All product descriptions and articles provided on this website are intended strictly for informational and educational purposes. Our products are designed exclusively for in-vitro research (i.e., experiments conducted outside of a living organism, typically in glassware such as test tubes or petri dishes). These compounds are not approved by the FDA for use in humans or animals. They are not medications, nor are they intended to diagnose, treat, prevent, or cure any disease or medical condition. Any bodily administration-human or animal-is strictly prohibited by law. Our products are not for human consumption under any circumstances.
Over one billion people are projected to be living with obesity by 2025, making it not just a global health crisis but a defining challenge of our era. As waistlines continue to expand worldwide and traditional interventions fall short, a new wave of therapies is emerging, with Cagrilintide leading the charge in innovative obesity management.
If advancing metabolic research is your priority, Prime Lab Peptides is the right place to begin exploring Cagrilintide. Our scientifically backed, cutting-edge research peptides are produced with precision and purity to support meaningful in-vitro studies. Whether you are initiating new investigations or expanding existing projects, Prime Lab Peptides provides reliable materials and rigorous quality to help you generate real, lasting insights.
What is Cagrilintide?
Cagrilintide[1] is a long-acting analogue of amylin, a naturally occurring hormone involved in appetite regulation and glucose control. Unlike earlier drugs such as pramlintide, cagrilintide’s unique structure enhances its stability and duration of action.
Its most exciting feature is its ability to bind selectively to the amylin receptors (AMY1R and AMY3R) in the brain, setting off a series of signals that lower food intake and maintain body weight loss, particularly by reducing fat mass while preserving lean muscle.
Recent studies[2] show that cagrilintide’s mechanism is distinct from popular GLP-1 agonists like semaglutide, acting on complementary neuronal pathways to control satiety and caloric intake.
Why Choose Cagrilintide? Top Benefits Explained
Cagrilintide offers significant benefits for weight management, helping patients achieve meaningful and sustained fat loss while preserving lean muscle. It effectively suppresses appetite and improves metabolic health[3], making it a powerful option alone or combined with semaglutide.
Benefits of Cagrilintide:
- Promotes substantial and sustained weight loss (over 20% with combo therapy).
- Primarily reduces fat mass while maintaining lean muscle.
- Strong appetite suppression via central satiety receptors.
- Improves metabolic markers like blood sugar, blood pressure, and waist circumference.
- Well tolerated with mostly mild gastrointestinal side effects.
- Effective as monotherapy or in combination with semaglutide for enhanced results.
How Does Cagrilintide Work in the Body?
Cagrilintide works by activating specific amylin receptors in the hindbrain, distinct from GLP-1 agonists, to reduce food intake and sustain body weight loss, primarily by lowering fat mass while preserving lean muscle. Its mechanism complements GLP-1 therapies, enabling greater patient benefit when combined.
This combination therapy, exemplified by the co-formulation “CagriSema,[4]” enhances weight loss beyond what either drug can achieve alone by synergistically slowing gastric emptying and boosting satiety signals, leading to more effective and sustained metabolic improvements. This is how it works:
1- Amylin Receptor Activation
Cagrilintide targets AMY1R and AMY3R in the area postrema, NTS, and LPBN, driving satiety by central neuron activation and reduced appetite.
2- Sustained Fat Loss
Cagrilintide produces lasting weight reduction mostly by decreasing fat mass, not just water or muscle, unlike many older obesity drugs.
3- Combination Synergy
Used alongside GLP-1 agonists, cagrilintide’s unique pathway enhances total weight loss and mitigates hunger rebound, allowing better long-term results.
4- Distinctiveness
Unlike traditional medications, it does not require daily intense dieting or sacrifice muscle mass, supporting healthier body composition.
Clinical Evidence: What Do Trials Show?
Cagrilintide has emerged from clinical trials as a highly promising agent for obesity treatment, demonstrating clear, dose-dependent efficacy in reducing body weight and waist circumference. Early-phase studies have laid the foundation for its therapeutic potential, with subsequent trials highlighting its synergistic benefits when combined with GLP-1 receptor agonists like semaglutide.
- A Phase 2 trial[5] demonstrated dose-dependent weight loss with cagrilintide, reaching up to 10.8% reduction over 26 weeks, along with significant decreases in waist circumference, indicating fat loss The Lancet, 2021.
- In the REDEFINE 2 Phase 3 trial[6], cagrilintide combined with semaglutide led to an average 13.7% weight loss at 68 weeks, compared to 3.4% with placebo, with 60% of participants achieving ≥20% weight loss NEJM, 2025.
- This combo also improved metabolic markers: 73.5% reached target HbA1c ≤6.5%, and significant reductions occurred in blood pressure and lipid profiles NEJM, 2025.
- Cagrilintide showed a better tolerability profile than earlier amylin analogues, with mostly mild-to-moderate gastrointestinal side effects that often diminished over time eBioMedicine, 2025.
- Compared to salmon calcitonin (sCT), cagrilintide is more stable and effective due to its shorter receptor binding time and selective action on AMY1R and AMY3R, avoiding adverse effects like lean mass loss eBioMedicine, 2025.
- Mechanistic studies confirm that activation of AMY1R and AMY3R is essential for fat mass reduction and lean mass preservation, reinforcing cagrilintide’s targeted action in obesity treatment eBioMedicine, 2025.
Advance Metabolic Research with Prime Lab Peptides: Explore the Future of Cagrilintide.
Cagrilintide is advancing through Phase 2/3 clinical trials, showing significant promise in combination approaches, particularly alongside semaglutide. Early findings suggest strong potential for uncovering new mechanisms in weight regulation, glucose control, and metabolic syndrome.
At Prime Lab Peptides, we supply high-purity cagrilintide for in-vitro research, supporting scientists in exploring its therapeutic potential and advancing the field of metabolic science. With rigorous quality standards and reliable access to emerging peptides, we enable researchers to stay ahead of breakthroughs that may shape the future of metabolic care. Browse our peptide portfolio today and accelerate your next discovery with Prime Lab Peptides.
FAQS
What is cagrilintide and how does it work for weight loss?
Cagrilintide is a long-acting amylin analogue that targets satiety receptors in the hindbrain to reduce appetite, decrease fat mass, and preserve lean muscle. It works differently but complements GLP-1 agonists like semaglutide for enhanced weight loss.
How effective is cagrilintide in clinical trials?
Phase 2 and 3 trials show dose-dependent weight loss up to 13.7% when combined with semaglutide, with significant waist circumference reduction and improved metabolic markers like HbA1c and blood pressure.
What are the common side effects of cagrilintide?
Most side effects are mild to moderate gastrointestinal symptoms such as nausea and vomiting, which typically decrease with continued treatment.
